SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes

NCT04889183 on ClinicalTrials.gov · last registry update 2025-04-22

A small phase 3 — 125 participants, against a typical 424. The sponsor logged completion for 28 May 2024. Primary outcome, as filed: Change from baseline to week 24 in urinary albumin:creatinine ratio (UACR). semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: University Medical Center Groningen
Sponsor type: Other
Enrollment: 125
Started: 2022-03-14
Primary completion: 2024-05-28 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change from baseline to week 24 in urinary albumin:creatinine ratio (UACR)

Conditions studied

Obesity · Albuminuria

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.